Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.62 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | MPO | P05164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31069232 | 0.86 | TAAR1 (0.58) | TAAR1AOC3IDO1MPOCYP1A2 | |
| SCHEMBL3520428 | 0.86 | TAAR1 (0.58) | TAAR1AOC3IDO1MPOCYP1A2 | |
| SCHEMBL19215809 | 0.84 | TAAR1 (0.56) | TAAR1AOC3IDO1MPOCYP1A2 | |
| SCHEMBL8526001 | 0.84 | TAAR1 (0.75) | TAAR1AOC3IDO1MPOLMNA | |
| SCHEMBL4574904 | 0.81 | TAAR1 (0.40) | TAAR1AOC3IDO1CYP1A2CYP2C19 | |
| SCHEMBL69225 | 0.79 | — | — | |
| SCHEMBL29602556 | 0.79 | — | — | |
| SCHEMBL30660239 | 0.79 | TAAR1 (0.68) | TAAR1AOC3IDO1MPOLMNA | |
| SCHEMBL23860531 | 0.77 | TAAR1 (0.52) | TAAR1AOC3IDO1CYP1A2CYP2C9 | |
| Phosphine SCHEMBL4870115 | 0.77 | TAAR1 (0.52) | TAAR1AOC3IDO1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4257593-A1 | CHIRAL MULTIDENTATE LIGAND AND USE THEREOF IN ASYMMETRIC HYDROGENATION | SHENZHEN CATALYS TECHNOLOGY CO., LTD. (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-9353107-B2 | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-9353107-B2 | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | disclosed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | disclosed |
| WO-2014006554-A1 | 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-01-09 | — | — | WO | disclosed |
| EP-1751131-A1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-14 | — | — | EP | disclosed |
| CN-1228330-C | Imidazole derivatives or their salts | SSP CO LTD (JP) | 2005-11-23 | — | — | CN | disclosed |
| WO-2005085226-A1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-15 | — | — | WO | disclosed |
| US-6852723-B2 | Aralkyl substituted piperazine compounds | CV THERAPEUTICS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| CN-1462270-A | Imidazole derivatives or their salts | SSP CO LTD (JP) | 2003-12-17 | — | — | CN | disclosed |
| US-20030176482-A1 | Imidazole derivatives or their salts | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2003-09-18 | — | — | US | disclosed |
| US-20030176440-A1 | Aralkyl substituted piperazine compounds | CV THERAPEUTICS, INC. | 2003-09-18 | — | — | US | disclosed |
| EP-1319658-A1 | IMIDAZOLE DERIVATIVES OR THEIR SALTS | SSP Co., Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
| US-6552023-B2 | N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life | CV THERAPEUTICS, INC. | 2003-04-22 | — | — | US | disclosed |
| CN-1404471-A | Substituted piperazine compounds | CV THERAPEUTICS INC (US) | 2003-03-19 | — | — | CN | disclosed |
| EP-1259493-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20010041704-A1 | N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life | CV THERAPEUTICS, INC. | 2001-11-15 | — | — | US | disclosed |
| WO-2001062744-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| EP-0289881-A2 | 2-Aminoalkyl-4-benzyl-1-(2H)-phthalazinone derivatives | ASTA Medica Aktiengesellschaft (DE) | 1988-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041704-A1 | N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life | TNNC1, ATP2A1, ATP2A2 | TAAR1 4462/4885AOC3 3775/4885IDO1 3116/4885 |
| US-20030176482-A1 | Imidazole derivatives or their salts | CSF3R, CSF1R, FLT3 | TAAR1 1392/4885AOC3 1428/4885IDO1 181/4885 |
| US-20030176440-A1 | Aralkyl substituted piperazine compounds | ATP2A1, ATP2A3, ATP2A2 | TAAR1 4289/4885AOC3 3574/4885IDO1 3076/4885 |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K6 | TAAR1 3590/4885AOC3 3895/4885IDO1 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.